Neridronate improves bone mineral density and reduces pain in β-thalassemia patients with osteoporosis: Results from a randomized, open-label study

Bone ◽  
2012 ◽  
Vol 50 ◽  
pp. S153
Author(s):  
G.L. Forni ◽  
A. Giusti⁎ ◽  
V. Pinto ◽  
S. Perrotta ◽  
C. Borgna Pignatti ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Mineral Density ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV‐Infected Adults on Tenofovir: A Randomized, Open‐Label Study

2019 ◽  
Vol 34 (12) ◽  
pp. 2192-2197 ◽  
Author(s):  
Andrew Carr ◽  
Stephen J Kerr ◽  
Robyn Richardson ◽  
Peter Ebeling ◽  
Nicholas Pocock ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Mineral Density ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Prolonged Effect

scholarly journals Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study

2012 ◽  
Vol 158 (2) ◽  
pp. 274-282 ◽  
Author(s):  
Gian Luca Forni ◽  
Silverio Perrotta ◽  
Andrea Giusti ◽  
Giovanni Quarta ◽  
Lorella Pitrolo ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Back Pain ◽  
Bone Mineral ◽  
Phase 2 ◽  
Mineral Density ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures—An open label study

Bone ◽  
2005 ◽  
Vol 36 (1) ◽  
pp. 47-51 ◽  
Author(s):  
Edit Tóth ◽  
Emőke Csupor ◽  
Szilvia Mészáros ◽  
Viktória Ferencz ◽  
Lóránd Németh ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Vertebral Fractures ◽  
Salmon Calcitonin ◽  
Male Osteoporosis ◽  
Mineral Density ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Bone Mineral Density during 3 years of Growth Hormone in previously GH-treated Young Adults with PWS

2021 ◽  
Author(s):  
Layla Damen ◽  
Lionne N. Grootjen ◽  
Stephany H. Donze ◽  
Laura C.g. de Graaff ◽  
Janielle A.e.m. van der Velden ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Growth Hormone ◽  
Young Adults ◽  
Bone Mineral ◽  
Mineral Density ◽  
Open Label ◽  
Gh Treatment ◽  
Positive Effects ◽  
Total Body ◽  
One Year

Objective: In children with Prader-Willi syndrome (PWS), growth hormone (GH) treatment has positive effects on bone mineral density (BMD). Two one-year studies did not show a difference between GH or placebo on BMD in young adults with PWS. However, there are no studies investigating BMD during longer-term GH treatment in young adults with PWS. Design: Open-label, prospective study in 43 young adults with PWS. Methods: BMD of the total body (BMDTBSDS) and lumbar spine (BMADLSSDS) measured by DXA. Results: In the total group, estimated mean (95% CI) BMDTB remained similar during 3 years of GH, being -0.76 (-1.11 to -0.41) SDS at start and -0.90 (-1.27 to -0.54) SDS after 3 years (p=0.11), as did BMADLS, being -0.36 (-0.72 to 0.01) SDS and -0.46 (-0.77 to -0.16) SDS resp. (p=0.16). In men, there was a significant decrease in BMDTBSDS during 3 years of GH, while BMADLSSDS remained similar. In women, both BMDTBSDS and BMADLSSDS remained similar. BMDTBSDS was associated with female sex, lean body mass and age. The majority of patients received sex steroid replacement therapy (SSRT). Conclusions: During 3 years of combined GH and SSRT treatment, BMD remained stable in the normal range in young adults with PWS. However, men showed a decline in BMDTBSDS, probably due to insufficient SSRT. We recommend to continue GH treatment in young adults with PWS and to start SSRT during adolescence unless puberty progresses normally.

Sign in / Sign up

Export Citation Format

Share Document